Bristol Myers Squibb (NYSE: BMY) reported that its experimental drug mezigdomide combined with carfilzomib and dexamethasone reduced the risk of disease progression or death by 52% compared to standard treatment in patients with relapsed or refractory multiple myeloma.

The Phase 3 SUCCESSOR-2 trial showed the combination treatment achieved a median progression-free survival of 18 months versus 8.3 months for the control group. The study included 479 patients, with 288 receiving the mezigdomide combination and 191 receiving the standard treatment.

Results were presented at the 2026 American Society of Clinical Oncology Annual Meeting. The trial demonstrated higher overall response rates with the mezigdomide combination at 80.2% compared to 53.4% for the control group. Complete response rates were 26.7% versus 8.9%.

The safety profile showed grade 3-4 treatment-related adverse events in 83.7% of patients receiving the mezigdomide combination compared to 56.5% in the control group. Neutropenia occurred in 61.1% versus 9.1% of patients, and infections in 34.0% versus 15.6%.

Study participants had a median age of 68, with 25.1% being 75 years or older. The median number of prior therapies was 2, and 92.1% of patients were triple-class-exposed. At data cutoff, median follow-up was 10.6 months.

Mezigdomide is an oral drug from Bristol Myers Squibb's targeted protein degradation platform designed to degrade specific proteins that lead to multiple myeloma cell death. The company plans to share results with health authorities.

The information is based on a company press release statement.